Table 1. Demographic characteristics of 330 women aged 15–44 years prescribed sodium valproate between 1 October 2017 and 1 January 2020 in East London
Age, yearsa n (%)
 15–1938 (12)
 20–2422 (7)
 25–2954 (16)
 30–3469 (21)
 35–3960 (18)
 ≥4087 (26)
Ethnic group a
 White150 (45)
 Black49 (15)
 South Asian87 (26)
 Other22 (7)
 Unknown22 (7)
Received pre-conception or contraception advice b 151 (46)
Prescribed contraception b 90 (27)
 Prescribed LARCc 48 (53)
 Prescribed non-LARCc 42 (47)
Received advice or contraception b 191 (58)
  • aData relate to most recent record for age and ethnic group. bAt least once during study period. cLong-acting reversible contraception (LARC): copper intrauterine device, levonorgestrel 13.5 mg/19.5 mg/52 mg intrauterine system, and progestogen-only implant. Non-LARC contraception: combined hormonal contraception including combined contraceptive pill, transdermal patch and vaginal ring, progestogen-only pill, progestogen-only injectable depot medroxyprogesterone acetate, condoms, and diaphragms.